Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Journal of Biopharmaceutical Statistics|March 1, 1993
A simple stopping rule for declaring treatment ineffectiveness in clinical trialsG G Enas, W W Offen
The American Journal of Gastroenterology|January 1, 1988
Effect of nizatidine and cimetidine on betazole-stimulated gastric secretion of normal subjects: comparison of effects on acid, water, and pepsinJ B Hammond, W W Offen
Journal of Medicine|January 1, 1985
Dose response to fenoprofen calcium using placebo and codeine as controlsW W Offen, C M Gruber
Digestive Diseases and Sciences|June 1, 1992
Nizatidine versus placebo in gastroesophageal reflux disease. A six-week, multicenter, randomized, double-blind comparison. Nizatidine Gastroesophageal Reflux Disease Study GroupM L Cloud, W W Offen
British Journal of Clinical Practice. Supplement|November 1, 1994
Nizatidine versus placebo in gastro-oesophageal reflux disease: a 6-week, multicentre, randomised, double-blind comparison. Nizatidine Gastroesophageal Reflux Disease Study GroupM L Cloud, W W Offen
Drugs|January 1, 1988
Pinacidil with and without hydrochlorothiazide. Dose-response relationships from results of a 4 x 3 factorial design studyM R Goldberg, W W Offen
Clinical Pharmacology and Therapeutics|September 1, 1992
Nizatidine versus placebo in active benign gastric ulcer disease: an eight-week, multicenter, randomized, double-blind comparison. The Nizatidine Benign Gastric Ulcer Disease Study GroupM L Cloud, N Enas, W W Offen
British Journal of Clinical Practice. Supplement|November 1, 1994
Nizatidine versus placebo in gastro-oesophageal reflux disease: a 12-week, multicentre, randomised, double-blind studyM L Cloud, W W Offen, M Robinson
The American Journal of Gastroenterology|December 1, 1991
Nizatidine versus placebo in gastroesophageal reflux disease: a 12-week, multicenter, randomized, double-blind studyM L Cloud, W W Offen, M Robinson
The American Journal of Psychiatry|October 27, 1997
Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonistA Satlin, N Bodick, W W Offen, et al.
Pageof 3